Sonnet BioTherapeutics Holdings, Inc.
SONN
$1.36
-$0.01-0.73%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 5,276.34% | -100.00% | -- | -- | -50.13% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5,276.34% | -100.00% | -- | -- | -50.13% |
| Cost of Revenue | 192.87% | 55.04% | -28.33% | -43.21% | -82.81% |
| Gross Profit | -41.69% | -55.21% | 27.21% | 42.67% | 83.14% |
| SG&A Expenses | 200.43% | 10.01% | 16.78% | -9.73% | -65.67% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 196.68% | -12.76% | -10.72% | -32.14% | -77.03% |
| Operating Income | -122.80% | 11.85% | 9.87% | 31.71% | 77.21% |
| Income Before Tax | -156.94% | 14.91% | 11.18% | 106.45% | 78.92% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -170.49% | 14.91% | 11.18% | 106.45% | 78.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -170.49% | 14.91% | 11.18% | 106.45% | 78.92% |
| EBIT | -122.80% | 11.85% | 9.87% | 31.71% | 77.21% |
| EBITDA | -123.11% | 11.86% | 9.88% | 31.73% | 77.26% |
| EPS Basic | 36.53% | 80.13% | 76.45% | 101.05% | 98.25% |
| Normalized Basic EPS | 39.71% | 80.13% | 76.45% | 101.05% | 98.25% |
| EPS Diluted | 36.53% | 80.13% | 76.45% | 100.93% | 98.25% |
| Normalized Diluted EPS | 39.71% | 80.13% | 76.45% | 100.99% | 98.25% |
| Average Basic Shares Outstanding | 326.12% | 328.38% | 277.07% | 515.35% | 1,107.89% |
| Average Diluted Shares Outstanding | 326.12% | 328.38% | 277.07% | 551.07% | 1,107.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |